Skip to content

Top Alliance

Next generation biopharmaceuticals

Home
Our Company
What we do
Our Research
- Pipeline
- COVID-19
TUOYI®
Expanded Access Policy
Media
Careers
Contact

Home
Our Company
What we do
Our Research
- Pipeline
- COVID-19
TUOYI®
Expanded Access Policy
Media
Careers
Contact

Donation History

[donation_history]

BLOG CATEGORIES

News(11)

RECENT COMMENTS

RECENT POSTS

Junshi Biosciences Receives FDA Breakthrough Therapy Designation for Toripalimab
October 13, 2020
Combination Study with JS016 and LY-CoV555 for Patients with Mild-to-Moderate COVID-19 Symptoms Met Primary and Secondary Endpoints
October 7, 2020
JUPITER-02 Phase III Global Study of Toripalimab at the Interim Analysis Met Pre-Specified Primary Endpoint of Progression-Free Survival in Recurrent or Metastatic Nasopharyngeal Carcinoma
September 28, 2020
Junshi Biosciences Receives FDA Breakthrough Therapy Designation for Toripalimab
September 10, 2020

TAGS

Art blog Design economy news The7 Web wordpress world

TopAlliance Biosciences Inc

© TOPALLIANCE BIOSCIENCES - 2023. All rights reserved.

company.info@topalliancebio.com